Peterson Rachel K, Choi Jeong Ha, King Tricia Z
Neuropsychology Department, Kennedy Krieger Institute, 1750 E. Fairmount Ave, Baltimore, MD, 21231, USA.
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Neurooncol. 2025 May;172(3):557-566. doi: 10.1007/s11060-025-04940-2. Epub 2025 Jan 28.
Medulloblastoma is the most commonly occurring malignant brain tumor of childhood. Treatment includes a combination of surgery, radiation therapy, and chemotherapy, all of which are associated with cognitive impairments. Despite appreciation of the value of neuropsychological evaluations to assess for cognitive impairments, there are barriers to these evaluations. This study aimed to identify potential demographic, medical, or neighborhood factors associated with barriers to neuropsychological evaluations.
Retrospective chart review identified pediatric patients with a medulloblastoma diagnosed between 2005 and 2024. Demographic, medical, and neighborhood factors were gleaned from the medical records.
Of the 67 identified patients, only 36 (53.73%) completed a clinical neuropsychological evaluation. Patients who obtained a neuropsychological evaluation were more likely to be non-Hispanic [X (1,62) = 9.20, p = <.01], diagnosed at younger ages [t(60) = - 8.40, p = < 0.001], treated with photon radiation therapy [X (1,62) = 15.24, p = < 0.001], live closer to the hospital [t(60) = 3.19, p = 0.001], and live in communities with higher health-related resources [t(60) = - 2.09, p = 0.02]. The two groups did not differ by any of the medical/clinical factors.
Neuropsychological evaluations assess for cognitive changes following cancer directed treatment, clarify other diagnostic possibilities (e.g., learning or attention difficulties), and facilitate access to appropriate accommodations and school- and community- based services. Although neuropsychological evaluations are recommended as standard of care following treatment for medulloblastoma, we identified demographic, medical, and neighborhood-level factors that serve as barriers to clinical neuropsychological evaluations. Implications for clinical care and recommendations to address these barriers are discussed.
髓母细胞瘤是儿童期最常见的恶性脑肿瘤。治疗包括手术、放射治疗和化疗的联合应用,所有这些治疗都与认知障碍有关。尽管认识到神经心理学评估对评估认知障碍的价值,但这些评估存在障碍。本研究旨在确定与神经心理学评估障碍相关的潜在人口统计学、医学或社区因素。
通过回顾性病历审查确定2005年至2024年间诊断为髓母细胞瘤的儿科患者。从病历中收集人口统计学、医学和社区因素。
在67例确诊患者中,只有36例(53.73%)完成了临床神经心理学评估。接受神经心理学评估的患者更有可能是非西班牙裔[X(1,62)=9.20,p=<.01],诊断时年龄较小[t(60)=-8.40,p=<0.001],接受光子放射治疗[X(1,62)=15.24,p=<0.001],居住地点离医院更近[t(60)=3.19,p=0.001],并且居住在与健康相关资源更多的社区[t(60)=-2.09,p=0.02]。两组在任何医学/临床因素方面均无差异。
神经心理学评估可评估癌症定向治疗后的认知变化;明确其他诊断可能性(如学习或注意力困难);并促进获得适当的便利措施以及基于学校和社区的服务。尽管建议将神经心理学评估作为髓母细胞瘤治疗后的标准护理,但我们确定了作为临床神经心理学评估障碍的人口统计学、医学和社区层面因素。讨论了对临床护理的影响以及解决这些障碍的建议。